Fundraising Fox

Day One Biopharmaceuticals

3 known investors

dayonebio.com ↗

Day One Biopharmaceuticals is an oncology drug developer that pursues a "search and development" strategy to bring targeted cancer medicines to patients of all ages, with a focus on pediatric low-grade glioma (pLGG). The company is part of Servier.

BiotechHealthtechin /dayonebio@DayOneBio

Investors · 3

Access BiotechnologyNew York City
Atlas VentureCambridge · $500K – $1M
Canaan PartnersStamford · $500K – $20M

In the news

Day One Biopharmaceuticals Stock - Long-term oncology pipeline in focusad-hoc-news.de · Jun 2026Day One Biopharmaceuticals beats revenue estimates By Investing.cominvesting.com · Feb 2026Day One Biopharmaceuticals earnings up next after Mersana deal By Investing.cominvesting.com · Feb 2026Day One Biopharmaceuticals secures $175 million in funding By Investing.cominvesting.com · Jul 2024Day One Biopharma Raises $60M in Series A Funding - FinSMEsfinsmes.com · May 2020

Frequently asked questions

What does Day One Biopharmaceuticals do?
Day One Biopharmaceuticals is an oncology drug developer that pursues a "search and development" strategy to bring targeted cancer medicines to patients of all ages, with a focus on pediatric low-grade glioma (pLGG). The company is part of Servier.
Who are Day One Biopharmaceuticals's investors?
Day One Biopharmaceuticals's investors include Access Biotechnology, Atlas Venture, Canaan Partners.